Inari Medical, INC
Market Movers (8-K)
Stryker Corporation finalizes its acquisition of Inari Medical, Inc., marking the completion of a merger agreement initiated in January 2025.
Stryker Corporation has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, totaling approximately $4.9 billion, marking Stryker's entry into the high-growth peripheral vascular segment.
Inari Medical announced a 21% year-over-year revenue increase for the third quarter of 2024, along with an updated full-year revenue guidance.
Worse than expected
Inari Medical's Chief Financial Officer, Mitch Hill, will retire on October 1, 2024, and will be succeeded by Kevin Strange, the current SVP of Finance, Accounting, Strategy and Business Development.
Inari Medical announced a 23% year-over-year revenue increase for the second quarter of 2024, driven by strong adoption of its medical devices and global expansion, and raised its full-year revenue guidance.
Better than expected
Inari Medical announced a 23.3% year-over-year revenue increase for the first quarter of 2024, driven by increased adoption of their procedures and new products, and raised its full-year revenue guidance.
Better than expected
Quarterly Earnings (10-Q)
Inari Medical's Q3 2024 results show a revenue increase of 21.4% year-over-year, but a net loss of $18.4 million due to higher operating expenses.
Worse than expected
Inari Medical's second quarter 2024 results show a revenue increase of 22.5% year-over-year, alongside a net loss due to higher operating expenses.
Worse than expected
Inari Medical's first quarter 2024 results show a revenue increase of 23.3% year-over-year, but also a significant increase in net loss.
Worse than expected
Annual Reports (10-K)
10-K: Inari Medical, Inc. Outlines Performance-Based Stock Unit Grants and Reports 2023 Financial Results
Inari Medical, Inc. details performance-based restricted stock unit grants tied to revenue targets and reports a revenue of $493.6 million with a net loss of $1.6 million for 2023.
Capital raise
Better than expected
Insider Trading (Form 4)
Director Robert Keith Warner reports the cancellation of Inari Medical shares and restricted stock units following the merger with Stryker Corporation, with shareholders receiving $80.00 per share.
Thomas Tu, Chief Medical Officer of Inari Medical, reports the cancellation and conversion of stock and options into cash following the merger with Stryker Corporation on February 19, 2025.
Director Catherine Szyman reports the disposition of Inari Medical shares and derivative securities following the merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Form 4: Inari Medical CFO Kevin Strange Reports Beneficial Ownership Changes Following Stryker Merger
Following the merger of Inari Medical with Stryker Corporation, CFO Kevin Strange reports changes in his beneficial ownership of Inari Medical securities.
Karen Silva, Principal Accounting Officer of Inari Medical, reports the acquisition of Inari Medical by Stryker Corporation, resulting in the cancellation of her common stock and restricted stock units in exchange for $80 per share.
Form 4: Inari Medical Director Jonathan Root Reports Acquisition by Stryker, Cash-Out of Shares and RSUs
Director Jonathan Root reports the acquisition of Inari Medical by Stryker Corporation, resulting in the cash-out of his shares and restricted stock units (RSUs) at $80.00 per share.
Proxy Statements (Def-14A)
Inari Medical will hold its annual stockholders meeting on April 24, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.
Inari Medical's upcoming annual meeting on April 24, 2024, will address director elections, auditor ratification, and executive compensation.